Nanobiotix S.A. (0QAV.L)

EUR 3.48

(1.75%)

EBITDA Summary of Nanobiotix S.A.

  • Nanobiotix S.A.'s latest annual EBITDA in 2023 was -34.01 Million EUR , up 51.65% from previous year.
  • Nanobiotix S.A.'s latest quarterly EBITDA in 2024 Q2 was -23.24 Million EUR , down 0.0% from previous quarter.
  • Nanobiotix S.A. reported an annual EBITDA of -53.78 Million EUR in 2022, down -1.56% from previous year.
  • Nanobiotix S.A. reported an annual EBITDA of -47.25 Million EUR in 2021, down -29.9% from previous year.
  • Nanobiotix S.A. reported a quarterly EBITDA of -27.92 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • Nanobiotix S.A. reported a quarterly EBITDA of 1.41 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of Nanobiotix S.A. (2023 - 2012)

Historical Annual EBITDA of Nanobiotix S.A. (2023 - 2012)

Year EBITDA EBITDA Growth
2023 -34.01 Million EUR 51.65%
2022 -53.78 Million EUR -1.56%
2021 -47.25 Million EUR -29.9%
2020 -34.86 Million EUR 21.69%
2019 -46.78 Million EUR -44.31%
2018 -32.18 Million EUR -15.74%
2017 -28.94 Million EUR -13.01%
2016 -24.95 Million EUR -22.36%
2015 -20.12 Million EUR -120.48%
2014 -9.31 Million EUR -17.2%
2013 -7.94 Million EUR -58.71%
2012 -5.79 Million EUR 0.0%

Peer EBITDA Comparison of Nanobiotix S.A.

Name EBITDA EBITDA Difference
Boiron SA 80.67 Million EUR 142.166%
Laboratorios Farmaceuticos Rovi, S.A. 238.01 Million EUR 114.293%
Vetoquinol SA 104.58 Million EUR 132.529%
Valneva SE -64.51 Million EUR 47.271%
AB Science S.A. -9.28 Million EUR -266.545%
PHAXIAM Therapeutics S.A. -22.93 Million EUR -48.36%
Vivoryon Therapeutics N.V. -28.35 Million EUR -19.984%
BioSenic S.A. -6.79 Million EUR -400.574%
ABIVAX Société Anonyme -133.2 Million EUR 74.462%
Formycon AG 81.05 Million EUR 141.971%